Livzan M A, Lapteva I V, Krolevets T S
Eksp Klin Gastroenterol. 2016(7):25-31.
To evaluate the diagnostic value of MMP-9, TIMP-1 and 2 as non-invasive markers of liver fibrosis in the NAFLD to improve the management of patients with this pathology.
We examined 99 patients with NAFLD and different stages of fibrosis, 83 men, 16 women, median age 45 (range 40-55) years. We assessed of risk factors for liver fibrosis in the NAFLD, anthropometric indicators, biochemical analysis of blood, abdominal ultrasonic studies, the levels of MMP-9, TIMP-1 and 2. Depending on the stage of fibrosis (0-4), established as a result of liver elastometry (Fibroscan), patients were divided into 5 groups: n = 27, n = 22, n = 23, n = 14, n = 13, respectively.
Between the groups in medical history, physical examination, calculation of BMI and the ratio of waist to hip volume (W/H) no significant differences were found. 64,6% of patients had abdominal obesity (BMI - 31,5 (29,1-33,9), W/H - 1,02 (1,01-1,05). Obesity and abdominal obesity (BMI, W/H) had a significant positive relationship of moderate streight (rs = (0,257), p < 0,04, rs = (0,301), p < 0,02, respectively), with the stage of liver fibrosis. The groups were significant differences in the level of glucose, total bilirubin (p < 0,04, p < 0,03, respectively). At the time of the examination, 57,5% of patients had steatosis, other patients had steatohepatitis. No significant differences in the level of liver function tests (ALT, AST) in the study groups were found. Significant differences were found in level of TIMP-2 (p < 0,04). TIMP-2 had a significant positive correlation with the severity of fibrosis in the hepatic tissue (rs = (0,349), p < 0,004).
TIMP-2 may be considered as a potential non-invasive marker for the diagnosis of liver fibrosis in patients with NAFLD.
评估基质金属蛋白酶-9(MMP-9)、金属蛋白酶组织抑制因子-1(TIMP-1)和金属蛋白酶组织抑制因子-2(TIMP-2)作为非酒精性脂肪性肝病(NAFLD)肝纤维化无创标志物的诊断价值,以改善对此类病症患者的管理。
我们检查了99例不同纤维化阶段的NAFLD患者,其中83例男性,16例女性,中位年龄45岁(范围40 - 55岁)。我们评估了NAFLD患者肝纤维化的危险因素、人体测量指标、血液生化分析、腹部超声检查以及MMP-9、TIMP-1和TIMP-2的水平。根据肝脏弹性测定法(Fibroscan)确定的纤维化阶段(0 - 4期),患者被分为5组,每组分别为n = 27、n = 22、n = 23、n = 14、n = 13。
在病史、体格检查、体重指数(BMI)计算以及腰臀比(W/H)方面,各组之间未发现显著差异。64.6%的患者存在腹型肥胖(BMI - 31.5(29.1 - 33.9),W/H - 1.02(1.01 - 1.05))。肥胖和腹型肥胖(BMI、W/H)与肝纤维化阶段呈显著正相关,相关性为中等强度(rs =(0.257),p < 0.04;rs =(0.301),p < 0.02)。各组在血糖、总胆红素水平上存在显著差异(分别为p < 0.04,p < 0.03)。在检查时,57.5%的患者有脂肪变性,其他患者有脂肪性肝炎。研究组在肝功能检查(谷丙转氨酶(ALT)、谷草转氨酶(AST))水平上未发现显著差异。在TIMP-2水平上发现了显著差异(p < 0.04)。TIMP-2与肝组织纤维化严重程度呈显著正相关(rs =(0.349),p < 0.004)。
TIMP-2可被视为NAFLD患者肝纤维化诊断的潜在无创标志物。